About this Research Topic
Head and neck squamous cell carcinoma (HNSCC) is the seventh most common malignancy worldwide and develop from the mucosal epithelium in the oral cavity, pharynx and larynx. Traditional HNSCC risk factors include alcohol and smoking however there is a rising incidence in human papillomavirus (HPV)-related HNSCC. The primary treatment for logo-regionally advanced HNSCC is either chemoradiotherapy or surgery followed by adjuvant radiation chemotherapy. Given high rates of disease recurrence, additional research is required to understand how to improve the prognosis and survival rates.
In the recurrent/metastatic setting, immune checkpoint blockade with PD-1 antibodies have now become the standard of care. Neoadjuvant immunotherapy trials either as monotherapy or in combination with other therapies have showed promising results to improve survival outcomes. Numerous studies are on-going.
The goal of this Research Topic is to generate a discussion of how neoadjuvant therapy affects HNSCC patients and the potential benefits, challenges and ongoing research which could provide valuable insights into improving treatment outcomes and patient quality of life. We welcome Original Research, Reviews, Systematic Reviews and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
In the recurrent/metastatic setting, immune checkpoint blockade with PD-1 antibodies have now become the standard of care. Neoadjuvant immunotherapy trials either as monotherapy or in combination with other therapies have showed promising results to improve survival outcomes. Numerous studies are on-going.
The goal of this Research Topic is to generate a discussion of how neoadjuvant therapy affects HNSCC patients and the potential benefits, challenges and ongoing research which could provide valuable insights into improving treatment outcomes and patient quality of life. We welcome Original Research, Reviews, Systematic Reviews and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: HNSCC, oncology, cancer, therapy, immunotherapy, head and neck
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
